EA202190331A1 - Композиции терапевтически активных частиц с модифицированной поверхностью, полученные путем ультрабыстрой заморозки - Google Patents

Композиции терапевтически активных частиц с модифицированной поверхностью, полученные путем ультрабыстрой заморозки

Info

Publication number
EA202190331A1
EA202190331A1 EA202190331A EA202190331A EA202190331A1 EA 202190331 A1 EA202190331 A1 EA 202190331A1 EA 202190331 A EA202190331 A EA 202190331A EA 202190331 A EA202190331 A EA 202190331A EA 202190331 A1 EA202190331 A1 EA 202190331A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compositions
therapeutically active
modified surface
active particles
surface obtained
Prior art date
Application number
EA202190331A
Other languages
English (en)
Inventor
III Роберт О. Уилльямс
Чэхо Мун
Алан Б. Уоттс
Джон Дж. Коуленг
Original Assignee
Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем filed Critical Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем
Publication of EA202190331A1 publication Critical patent/EA202190331A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

В изобретении описаны фармацевтические композиции, которые содержат менее 10% вспомогательного вещества и представлены в виде наноагрегатов. Было показано, что эти фармацевтические композиции демонстрируют улучшенные свойства, такие как улучшенные аэрозолизация и аэродинамические качества. Также в изобретении предложены способы получения описанных в данном документе фармацевтических композиций и их применения.
EA202190331A 2018-07-24 2019-07-24 Композиции терапевтически активных частиц с модифицированной поверхностью, полученные путем ультрабыстрой заморозки EA202190331A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862702674P 2018-07-24 2018-07-24
PCT/US2019/043202 WO2020023614A1 (en) 2018-07-24 2019-07-24 Compositions of surface-modified therapeutically active particles by ultra-rapid freezing

Publications (1)

Publication Number Publication Date
EA202190331A1 true EA202190331A1 (ru) 2021-06-17

Family

ID=69181152

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202190331A EA202190331A1 (ru) 2018-07-24 2019-07-24 Композиции терапевтически активных частиц с модифицированной поверхностью, полученные путем ультрабыстрой заморозки

Country Status (12)

Country Link
US (1) US20210338671A1 (ru)
EP (1) EP3827260A4 (ru)
JP (2) JP7611813B2 (ru)
KR (1) KR20210038583A (ru)
CN (1) CN112673257B (ru)
AU (1) AU2019311086B2 (ru)
BR (1) BR112021001290A2 (ru)
CA (1) CA3106618A1 (ru)
EA (1) EA202190331A1 (ru)
IL (1) IL280342A (ru)
MX (1) MX2021000796A (ru)
WO (1) WO2020023614A1 (ru)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014186754A2 (en) 2013-05-16 2014-11-20 Board Of Regents The University Of Texas System Dry solid aluminum adjuvant-containing vaccines and related methods thereof
US11918646B2 (en) 2017-12-11 2024-03-05 Board Of Regents, The University Of Texas System Dry adjuvanted immune stimulating compositions and use thereof for mucosal administration
CN113398079B (zh) * 2020-03-16 2024-01-19 鲁南制药集团股份有限公司 一种注射用氟达拉滨冻干粉
CN116033891A (zh) * 2020-09-03 2023-04-28 菲利普莫里斯生产公司 冷冻干燥的低吸湿性活性粉末组合物
JP2023540190A (ja) 2020-09-03 2023-09-22 フィリップ・モーリス・プロダクツ・ソシエテ・アノニム 低吸湿性活性粉末組成物
US11793808B2 (en) 2021-02-22 2023-10-24 Mannkind Corp. Compositions of clofazimine, combinations comprising them, processes for their preparation, uses and methods comprising them
US20220313611A1 (en) * 2021-03-12 2022-10-06 Board Of Regents, The University Of Texas System Methods to prepare dry powders using suspension based thin film freezing
US12015755B2 (en) 2021-03-25 2024-06-18 Korea Advanced Institute Of Science And Technology Real-time omnidirectional stereo matching method using multi-view fisheye lenses and system thereof
CN113484469B (zh) * 2021-06-30 2022-11-18 中国科学院青海盐湖研究所 水合盐体系相变储能材料纳米尺度相分离的原位表征方法
CN116440084A (zh) * 2022-01-07 2023-07-18 浙江萃泽医药科技有限公司 一种可吸入的药物粉末制剂及其制备方法
KR20250100660A (ko) 2022-10-25 2025-07-03 베라더믹스 인코포레이티드 변형 방출 미녹시딜의 조성물 및 사용 방법

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08310969A (ja) * 1995-05-22 1996-11-26 Lion Corp 固形薬品組成物及びその製造方法
US7521068B2 (en) * 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
CN1750811A (zh) * 2001-10-19 2006-03-22 巴克斯特国际公司 在冷冻水基质中包括颗粒的稳定组合物
GB0321607D0 (en) * 2003-09-15 2003-10-15 Vectura Ltd Manufacture of pharmaceutical compositions
EP1789018A1 (en) * 2004-08-27 2007-05-30 The Dow Chemical Company Enhanced delivery of drug compositions to treat life threatening infections
WO2007011396A2 (en) * 2004-10-29 2007-01-25 President And Fellows Of Harvard College Particles for treatment of pulmonary infection
US8361439B1 (en) * 2005-01-04 2013-01-29 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
JP2009514902A (ja) * 2005-11-11 2009-04-09 バイオラブ・サヌス・ファーマセウティカ・エルティーディーエー． 凝集ナノ粒子を含む固体医薬組成物及びその生成方法
US20120269721A1 (en) * 2009-10-12 2012-10-25 The Regents Of The University Of California Targeted nanoclusters and methods of their use
US20140239525A1 (en) * 2011-06-17 2014-08-28 Board Of Regents, University Of Texas System Inhalable pharmaceutical compositions
IN2012DE00674A (ru) * 2012-03-07 2015-08-21 Nat Inst Of Pharmaceutical Education And Res Niper
BR112017023351B1 (pt) * 2015-05-01 2023-11-28 Board Of Regents, The University Of Texas System Composição farmacêutica e uso da composição farmacêutica

Also Published As

Publication number Publication date
KR20210038583A (ko) 2021-04-07
JP7611813B2 (ja) 2025-01-10
EP3827260A4 (en) 2022-05-04
CN112673257A (zh) 2021-04-16
AU2019311086A1 (en) 2021-02-04
CA3106618A1 (en) 2020-01-30
WO2020023614A1 (en) 2020-01-30
IL280342A (en) 2021-03-25
EP3827260A1 (en) 2021-06-02
MX2021000796A (es) 2021-06-15
CN112673257B (zh) 2025-02-25
AU2019311086B2 (en) 2026-06-04
JP2021530551A (ja) 2021-11-11
BR112021001290A2 (pt) 2021-04-27
JP2024170583A (ja) 2024-12-10
US20210338671A1 (en) 2021-11-04

Similar Documents

Publication Publication Date Title
MX2021000796A (es) Composiciones de partículas terapéuticamente activas con superficie modificada por congelación ultra-rápida.
MX2023004923A (es) Compuestos heterociclicos como inmunomoduladores.
MX2022005290A (es) Compuestos heterociclicos como inmunomoduladores.
PH12018502710A1 (en) Heterocyclic compounds as immunomodulators
MX2024012899A (es) Metodos y composiciones relacionadas con crispr/cas para el tratamiento de beta hemoglobinopatias
WO2018237037A3 (en) HEAVY CHAIN ANTIBODY ONLY ANTI-BCMA
MY199220A (en) Heterocyclic compounds as immunomodulators
PH12020550964A1 (en) Heavy chain antibodies binding to cd22
MY196319A (en) Polycyclic TLR7/8 Antagonists and use Thereof in the Treatment of Immune Disorders
MX2018007704A (es) Composicion farmaceutica que comprende lenalidomida amorfa y un antioxidante.
EP4306166A3 (en) Compounds, compositions and methods of use
WO2017218981A3 (en) Compositions and methods for reducing ocular neovascularization
WO2017112528A3 (en) Interleukin-15 compositions and uses thereof
WO2017214170A3 (en) Baff-r antibodies and uses thereof
PH12018502714A1 (en) Nicotine particles and compositions
CY1123623T1 (el) Θεραπεια νευρολογικων νοσων
WO2017053868A8 (en) C4-modified oleanolic acid derivatives for inhibition of il-17 and other uses
MX391708B (es) Metodos para tratar trastornos del desarrollo con gaboxadol.
WO2018226992A8 (en) Tau aggregation inhibitors
MX2018011162A (es) Metodos de purificacion de colageno 7.
MX2020002769A (es) Composiciones de polvo seco con estearato de magnesio.
SA520420261B1 (ar) تركيبات إرنوماب واستخداماتها
PH12016501519B1 (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
WO2015106215A3 (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
WO2019036725A3 (en) PEPTIDE INHIBITORS OF TAU AGGREGATION